ACM
EPZM

Altium Capital Management’s Epizyme, Inc EPZM Stock Holding History

Altium Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-130,000
Closed -$1.41M – 149
2020
Q4 		$1.41M Buy
+130,000
New +$1.6M 0.53% 75

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Altium Capital Management's EPZM Position: Q1 2021 in Review

Altium Capital Management sold out of Epizyme, Inc (EPZM) in Q1 2021, closing a stake of 130,000 shares — an estimated $1.41M sold.

Altium Capital Management first reported a position in EPZM in Q4 2020 and held it in 1 quarter. The position peaked at $1.41M in Q4 2020. 137 funds tracked by Wall St. Rank hold EPZM as of Q1 2021.

  • Altium Capital Management reported no remaining Epizyme, Inc position as of Q1 2021 after selling out during the quarter.
  • Altium Capital Management sold 130,000 Epizyme, Inc shares in Q1 2021, an estimated $1.41M.
  • Altium Capital Management first reported a position in Epizyme, Inc in Q4 2020 and held it in 1 quarter.
  • Altium Capital Management's Epizyme, Inc position peaked at $1.41M in Q4 2020.
  • 137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2021.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.